Author:
Kind Christian,Nadal D.,Wyler C. -A.,Siegrist C. -A.,Cheseaux J. J.,Vaudaux B.,Fawer C. -L.,Rudin C.,Schaad U. B.,Aebi C.,Baumgartner C.,Gnehm H. E.,Schubiger G.,Klingler J.,Hunziker U.,Kuchler H. F.,Gianinazzi M. P.,Bühlmann U.,Biedermann K.,Irion O.,Spoletin G.,Schüpbach J.,Boni J.,Jendis J.,Tomasik Z.,
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference14 articles.
1. Centres for Disease Control (1986) Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 35: 334–339
2. Centres for Disease Control (1994) Recommendations of the U.S. public health service task force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 43/RR-11: 1–20
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye MS, Stratton P, Balsley J, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331: 1173–1180
4. Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
5. Dunn D, Newell ML, Mayaux MJ, Kind C, Hutto C, Goedert JJ, Andiman W, Perinatal AIDS Collaborative Transmission Studies (1994) Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. J-Acquir Immune Def Syn 7: 1064–1066